On ECHEMI
Home > Drugs > Hubei KEYI Pharmaceutical Industry Co., Ltd.
Hubei KEYI Pharmaceutical Industry Co., Ltd.
  • Founded in:

    1997-05-23
  • Country:

    China China
  • Address:

    No. 8, Huanglongshan South Road, East Lake New Technology Development Zone, Wuhan
  • Tax NO.:

    91420000726103295U
  • Registered Funds:

    34.750206 million yuan
  • Email:

Related Drugs
Ribavirin
Ribavirin
Name Description Content CAS NO. Registered Holders
Ribavirin

Extract from the above information

More

Extract from the above information

36791-04-5 33
Andrographolide Tablets
Each tablet contains andrographolide m,.
Name Description Content CAS NO. Registered Holders
Andrographolide

5508-58-7 6
Nephritis Four-flavor Granule
Lespedeza serrata, Scutellaria baicalensis, Pyrrosia odoratum, Astragalus membranaceus.
Name Description Content CAS NO. Registered Holders
HERBA LESPEDEZAE

0
RADIX SCUTELLARIAE

0
Shi Wei Ti extract

0
Astragali Radix

0
Imiquimod
Name Description Content CAS NO. Registered Holders
Imiquimod

Extract from the above information

More

Extract from the above information

99011-02-6 16
Penciclovir cream
The main ingredient of this product is: Penciclovir. Its chemical name is: 9-[4-hydroxy-3-(hydroxymethyl)-butyl]-guanine.
Name Description Content CAS NO. Registered Holders
Penciclovir

This product is a nucleoside antiviral drug, which has an inhibitory effect on type I and type II herpes simplex viruses in vitro. In virus-infected cells, viral thymidine deoxynucleoside kinase phosphorylates this product into penciclovir monophosphate, and then cellular kinase converts penciclovir monophosphate into penciclovir triphosphate. In vitro experiments have shown that penciclovir triphosphate and deoxyguanosine triphosphate competitively inhibit herpes simplex virus polymerase, thereby selectively inhibiting the synthesis and inhibition of herpes simplex virus DNA. The generation of herpes simplex virus mutants resistant to this product is due to changes in the properties of viral thymidine deoxynucleoside kinase or DNA polymerase. The most common acyclovir-resistant virus mutants lack thymidine kinase, and they are also resistant to this product.

More

This product is a nucleoside antiviral drug, which has an inhibitory effect on type I and type II herpes simplex viruses in vitro. In virus-infected cells, viral thymidine deoxynucleoside kinase phosphorylates this product into penciclovir monophosphate, and then cellular kinase converts penciclovir monophosphate into penciclovir triphosphate. In vitro experiments have shown that penciclovir triphosphate and deoxyguanosine triphosphate competitively inhibit herpes simplex virus polymerase, thereby selectively inhibiting the synthesis and inhibition of herpes simplex virus DNA. The generation of herpes simplex virus mutants resistant to this product is due to changes in the properties of viral thymidine deoxynucleoside kinase or DNA polymerase. The most common acyclovir-resistant virus mutants lack thymidine kinase, and they are also resistant to this product.

39809-25-1 12
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.